RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences but lowers the price target from $85 to $75.
October 08, 2024 | 6:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Edwards Lifesciences but reduces the price target from $85 to $75, indicating a more cautious outlook.
The maintained Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook, likely due to market conditions or company-specific factors. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100